Albatroz Therapeutics, a Singapore-based biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, raised $3M in funding.
The round was led by Outram Bio and SEEDS Capital. Christopher Tan, Partner at Outram Bio, has been appointed to Albatroz’s Board of Directors.
The company intends to use the funds to accelerate the development of therapeutic antibodies against a novel target that degrades the extracellular matrix, a key contributor to cancer and arthritis.
Founded in 2020 and led by CEO Dr. Fred Bard, Albatroz Therapeutics is a biotechnology company developing antibody therapeutics to treat solid tumors and arthritic disorders. The company holds a license for rights to the technology patent portfolio and is conducting further target validation, drug development, and preclinical studies.
FinSMEs
25/04/2023